US Patent

US12064487 — Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process

Method of Use · Assigned to Guerbet SA · Expires 2040-01-17 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA, and its preparation and purification process.

USPTO Abstract

The present invention relates to a complex of formula (II) constituted of at least 90% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae: The present invention also relates to a process for preparing and purifying said complex of formula (II), and also to a composition comprising said complex.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4424 — Elucirem
U-4424 — Elucirem
U-4424 — Elucirem
U-4424 — Elucirem
U-4424 — Elucirem
U-4424 — Elucirem

Patent Metadata

Patent number
US12064487
Jurisdiction
US
Classification
Method of Use
Expires
2040-01-17
Drug substance claim
No
Drug product claim
No
Assignee
Guerbet SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.